These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27930735)

  • 1. Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.
    White MK; Hu W; Khalili K
    PLoS Pathog; 2016 Dec; 12(12):e1005953. PubMed ID: 27930735
    [No Abstract]   [Full Text] [Related]  

  • 2. CRISPR-Cas based targeting of host and viral genes as an antiviral strategy.
    Koujah L; Shukla D; Naqvi AR
    Semin Cell Dev Biol; 2019 Dec; 96():53-64. PubMed ID: 30953741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.
    Najafi S; Tan SC; Aghamiri S; Raee P; Ebrahimi Z; Jahromi ZK; Rahmati Y; Sadri Nahand J; Piroozmand A; Jajarmi V; Mirzaei H
    Biomed Pharmacother; 2022 Apr; 148():112743. PubMed ID: 35228065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The CRISPR/Cas system: a genome editing tool to develop animal models of viral infections].
    Castino G; Guillemet M; Joly A; Vignon A
    Med Sci (Paris); 2018 May; 34(5):403-405. PubMed ID: 29900841
    [No Abstract]   [Full Text] [Related]  

  • 5. Harnessing CRISPR to combat human viral infections.
    de Buhr H; Lebbink RJ
    Curr Opin Immunol; 2018 Oct; 54():123-129. PubMed ID: 30056335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Strategies of Clustered Regularly Interspaced Palindromic Repeats-Cas Systems for Different Viral Infections.
    Wahid B; Usman S; Ali A; Saleem K; Rafique S; Naz Z; Ahsan Ashfaq H; Idrees M
    Viral Immunol; 2017 Oct; 30(8):552-559. PubMed ID: 28825529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge.
    Lee C
    Molecules; 2019 Apr; 24(7):. PubMed ID: 30959782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral infection: Phages' box of tricks for CRISPR.
    Attar N
    Nat Rev Microbiol; 2015 Nov; 13(11):660-1. PubMed ID: 26456927
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunity and Viral Infections: Modulating Antiviral Response via CRISPR-Cas Systems.
    Brezgin S; Kostyusheva A; Bayurova E; Volchkova E; Gegechkori V; Gordeychuk I; Glebe D; Kostyushev D; Chulanov V
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome Editing Strategies to Protect Livestock from Viral Infections.
    Söllner JH; Mettenleiter TC; Petersen B
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas-Mediated Resistance against Viruses in Plants.
    Khan ZA; Kumar R; Dasgupta I
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial DNA modification by CRISPR/Cas system: Challenges and future direction.
    Prakash R; Kannan A
    Prog Mol Biol Transl Sci; 2021; 178():193-211. PubMed ID: 33685597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of an immortalized renal cell line of the Chinese tree shrew (Tupaia belangeri chinesis).
    Gu T; Yu D; Li Y; Xu L; Yao YL; Yao YG
    Appl Microbiol Biotechnol; 2019 Mar; 103(5):2171-2180. PubMed ID: 30637496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex genome editing of microorganisms using CRISPR-Cas.
    Adiego-Pérez B; Randazzo P; Daran JM; Verwaal R; Roubos JA; Daran-Lapujade P; van der Oost J
    FEMS Microbiol Lett; 2019 Apr; 366(8):. PubMed ID: 31087001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
    Bae T; Hur JW; Kim D; Hur JK
    Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.